Vermont Lung Center

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Cystic fibrosis6 trials
• Asthma2 trials
• COPD1 trial
• High blood pressure1 trial
• Obesity1 trial
• Pulmonary arterial hypertension1 trial

Phase

• Phase 36 trials
• Phase 22 trials
• Phase 11 trial

Status

• Completed7 trials
• Active, not recruiting2 trials
• Enrolling by invitation1 trial

Lead sponsor

• Vertex Pharmaceuticals Incorporated6 trials
• Connect Biopharm LLC2 trials
• United Therapeutics1 trial
• University of Vermont1 trial

Running trials

• Enrolling by invitation

  Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

  NCT05844449· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

  NCT05444257· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

  NCT05422222· Phase 3· Vertex Pharmaceuticals Incorporated· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Cystic fibrosis1 recruiting

Closed trials

• Completed

  Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

  NCT06940154· Phase 2· Connect Biopharm LLC· Source

• Completed

  Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

  NCT06940141· Phase 2· Connect Biopharm LLC· Source

• Completed

  Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

  NCT06154447· Phase 1· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· United Therapeutics· Source

• Completed

  Increased Lung Volume as Controller Therapy for Asthma

  NCT02953431· University of Vermont· Source